Montag, 11. Januar 2016

Cliffnotes: Molecular targets downstream of CR

A very brief list and not a comprehensive one follows. I focus on direct evidence from KO models and lifespan studies, because this is the most robust study design. I don't care for surrogate endpoints, with the exception of pathology. The most common study design can be summarized thusly: When you combine "Factor X" with CR, does this affect the magnitude of LS extension from CR? Where X is either a gain of function (e.g. other LS extension) or loss of function (usually KO) intervention.

A. Direct evidence
B. Indirect evidence
C. Speculative or parallel pathways

A. Direct evidence

GH/IGF1